Numinus Wellness Inc. (TSX-V:NUMI, OTC:LKYSF) said it has advanced to the next implementation phase in a key post-traumatic stress disorder (PTSD) clinical trial by enrolling and dosing the first clinical trial volunteer in Canada.
The trial, titled: 'A multi-site open-label extension study of MDMA-assisted psychotherapy for PTSD (MAPPUSX)', is sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS) and organized by MAPS Public Benefit Corporation (MAPS PBC).
"Numinus is excited to administer the first MDMA-assisted therapy dosing of MDMA at our clinics and contribute to the growing body of MAPS' research,” Dr Joe Flanders, VP Psychology at Numinus said in a statement. "Designed with accessibility and ethics at its core, we look forward to the continuation of this study and translating the findings into clinical practice."
READ: Numinus Wellness says its research lab receives new biosecurity license for expansion
Numinus hosts the Canadian sites for the clinical trial through two purpose-designed clinics located in Montreal and Vancouver. This week, the Montreal site began drug administration. The treatment follows MAPS' protocol of three sessions of MDMA administration and therapy, each to be followed by three integration sessions. The full program is expected to complete in mid-summer 2022.
"We are proud of our clinical and research teams who have been and continue to be instrumental in driving MDMA-assisted therapy for PTSD research forward in Canada," said Payton Nyquvest, CEO and founder, Numinus.
"This week's trial progress is another step in our strengthening collaboration with MAPS as we work together to make psychedelic-assisted therapy accessible to those in need. We will continue to work with MAPS, Health Canada and the industry to help make MDMA-assisted therapy a reality,” Nyquvest concluded.